EKF Diagnostics Holdings PLC
LSE:EKF

Watchlist Manager
EKF Diagnostics Holdings PLC Logo
EKF Diagnostics Holdings PLC
LSE:EKF
Watchlist
Price: 25.22 GBX -0.12%
Market Cap: 114.4m GBX
Have any thoughts about
EKF Diagnostics Holdings PLC?
Write Note

Gross Margin
EKF Diagnostics Holdings PLC

48.1%
Current
48%
Average
47.2%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
48.1%
=
Gross Profit
24.5m
/
Revenue
51m

Gross Margin Across Competitors

Country UK
Market Cap 114.6m GBP
Gross Margin
48%
Country US
Market Cap 205.2B USD
Gross Margin
56%
Country US
Market Cap 193.1B USD
Gross Margin
67%
Country US
Market Cap 148.6B USD
Gross Margin
64%
Country US
Market Cap 132.9B USD
Gross Margin
69%
Country IE
Market Cap 109.9B USD
Gross Margin
65%
Country US
Market Cap 64.8B USD
Gross Margin
45%
Country DE
Market Cap 56.7B EUR
Gross Margin
38%
Country CN
Market Cap 325.5B CNY
Gross Margin
64%
Country US
Market Cap 42.2B USD
Gross Margin
79%
Country US
Market Cap 37.7B USD
Gross Margin
41%
No Stocks Found

EKF Diagnostics Holdings PLC
Glance View

Market Cap
114.4m GBX
Industry
Health Care

EKF Diagnostics Holdings Plc is a vitro diagnostics company, which designs and manufactures diagnostic equipment for use within point-of-care settings. The company is headquartered in Penarth, South Glamorgan. The company went IPO on 2002-06-05. The firm's point-of-care range includes hemoglobin analyzers, HbA1c analyzers and glucose analyzers for use in the screening, monitoring and diagnosis of patients, as well as rapid tests for pregnancy and common infectious diseases. Its Central Laboratory division includes a range of products for use in both large and small laboratory facilities. Its subsidiary, EKF Life Sciences, provides bulk diagnostic enzyme manufacturing and fermentation services. EKF Life Sciences specializes in producing enzymes, including Salicylate Hydroxylase and Beta-Hydroxybutyrate Dehydrogenase. Its products include Quo-Test A1c, Biosen, Quo-Lab A1c, UltraCrit, DiaSpect, HemataStat II and Creamatocrit Plus. The company operates in Germany, the United States, Russia and the United Kingdom.

EKF Intrinsic Value
32.01 GBX
Undervaluation 21%
Intrinsic Value
Price

See Also

Discover More
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
48.1%
=
Gross Profit
24.5m
/
Revenue
51m
What is the Gross Margin of EKF Diagnostics Holdings PLC?

Based on EKF Diagnostics Holdings PLC's most recent financial statements, the company has Gross Margin of 48.1%.